Cancer Research and Treatment

Volume 37(5); October 2005

Review Article

Epstein-Barr Virus in Human Malignancy: A Special Reference to Epstein-Barr Virus associated Gastric Carcinoma: Mee Soo Chang, Woo Ho Kim; Cancer Res Treat. 2005;37(5):257-267. Published online October 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.5.257

Epstein-Bar virus (EBV), a human herpesvirus, establishes a life-long persistent infection in 90~95% of human adult population worldwide. EBV is the etiologic agent of infectious mononucleosis, and EBV is associated with a variety of human malignancy including lymphoma and gastric carcinoma. Recently, EBV has been classified as group 1 carcinogen by the WHO International Agency for Research on Cancer. Evidence is presented which suggests that failures of the EBV-specific immunity may play a role in the pathogenesis of EBV-associated malignancy. At present, the precise mechanisms by which EBV transforms B lymphocytes have been disclosed. Encouragingly, they have had enough success so far to keep them enthusiastic about novel therapeutic trial in the field of EBV-associated lymphoma. However, information on EBV-associated gastric carcinoma is still at dawn. This article reviews EBV biology, immunological response of EBV infection, unique oncogenic property of EBV, peculiarity of EBV-associated gastric carcinoma, and lastly, EBV-targeted therapy and vaccination.

Citations

Citations to this article as recorded by

Current development of therapeutic vaccines for the treatment of chronic infectious diseases
Pil-Gu Park, Munazza Fatima, Timothy An, Ye-Eun Moon, Seungkyun Woo, Hyewon Youn, Kee-Jong Hong
Clinical and Experimental Vaccine Research.2024; 13(1): 21. CrossRef
Cutaneous Post-transplant Lymphoproliferative Disorder
Alpa Kanji, Raida Ahmad, Laksha Bala, Eleanor Mallon
Cureus.2024;[Epub] CrossRef
Clinicopathologic Characteristics of Trop Family Proteins (Trop-2 and EpCAM) in Gastric Carcinoma
Hye Sung Kim, Younghoon Kim, Hye Seung Lee
Journal of Gastric Cancer.2024; 24(4): 391. CrossRef
Características clínico-patológicas del adenocarcinoma gástrico asociado al virus de Epstein-Barr en una región de alta incidencia de cáncer gástrico en Colombia
A. Vidal-Realpe, R.A. Dueñas-Cuellar, V.E. Niño-Castaño, D.L. Mora-Obando, J.J. Arias-Agudelo, H.J. Bolaños
Revista de Gastroenterología de México.2023; 88(3): 256. CrossRef
Clinical and pathologic characteristics of gastric adenocarcinoma associated with Epstein-Barr virus in a region with a high incidence of gastric cancer in Colombia
A. Vidal-Realpe, R.A. Dueñas-Cuellar, V.E. Niño-Castaño, D.L. Mora-Obando, J.J. Arias-Agudelo, H.J. Bolaños
Revista de Gastroenterología de México (English Edition).2023; 88(3): 256. CrossRef
Iroquois Family Genes in Gastric Carcinogenesis: A Comprehensive Review
Everton Cruz dos Santos, Igor Petrone, Renata Binato, Eliana Abdelhay
Genes.2023; 14(3): 621. CrossRef
The role of viruses in cancer development versus cancer therapy: An oncological perspective
Hossein Javid, Alireza Sharbaf Mashhad, Shaghayegh Yazdani, Mahsa Akbari Oryani, Sanaz Akbari, Nastaran Rezagholinejad, Mahboubeh Tajaldini, Mehdi Karimi‐Shahri
Cancer Medicine.2023; 12(10): 11127. CrossRef
Could Immune Checkpoint Disorders and EBV Reactivation Be Connected in the Development of Hematological Malignancies in Immunodeficient Patients?
Paulina Mertowska, Sebastian Mertowski, Konrad Smolak, Gabriela Kita, Katarzyna Guz, Aleksandra Kita, Marcin Pasiarski, Jolanta Smok-Kalwat, Stanisław Góźdź, Ewelina Grywalska
Cancers.2023; 15(19): 4786. CrossRef
The Molecular Interplay between Human Oncoviruses and Telomerase in Cancer Development
Maria Lina Tornesello, Andrea Cerasuolo, Noemy Starita, Anna Lucia Tornesello, Patrizia Bonelli, Franca Maria Tuccillo, Luigi Buonaguro, Maria G. Isaguliants, Franco M. Buonaguro
Cancers.2022; 14(21): 5257. CrossRef
Epstein-Barr Virus Positive Mucocutaneous Ulceration: A case report
Hiraa Javed, Parkash L. Ramchandani
Advances in Oral and Maxillofacial Surgery.2021; 4: 100205. CrossRef
Recent Advances in Diagnostic Approaches for Epstein–Barr Virus
Mai Abdel Haleem Abusalah, Siew Hua Gan, Mohammad A. I. Al-Hatamleh, Ahmad Adebayo Irekeola, Rafidah Hanim Shueb, Chan Yean Yean
Pathogens.2020; 9(3): 226. CrossRef
Clinicopathological characteristics of Epstein-Barr virus-positive gastric cancer in Latvia
Evita Gasenko, Sergejs Isajevs, Maria Constanza Camargo, George Johan A. Offerhaus, Inese Polaka, Margaret L. Gulley, Roberts Skapars, Armands Sivins, Ilona Kojalo, Arnis Kirsners, Daiga Santare, Jelizaveta Pavlova, Olga Sjomina, Elina Liepina, Liliana Tz
European Journal of Gastroenterology & Hepatology.2019; 31(11): 1328. CrossRef
Low CD4 cells and viral co-infection increase the risk of VaIN: Use of SCCA1 and Ki67 as diagno-prognostic biomarkers
Jude Ogechukwu Okoye, Charles Erinle, Antony Ajuluchukwu Ngokere, Abimbola Jimoh
Pathophysiology.2018; 25(1): 51. CrossRef
Epigenetic Regulation of Tumor Suppressors byHelicobacter pyloriEnhances EBV-Induced Proliferation of Gastric Epithelial Cells
Saurabh Pandey, Hem Chandra Jha, Sanket Kumar Shukla, Meghan K. Shirley, Erle S. Robertson, Terence S. Dermody, Blossom Damania, Bala Chandran, Shou-Jiang Gao
mBio.2018;[Epub] CrossRef
Phylogenetic comparison of Epstein-Barr virus genomes
Su Jin Choi, Seok Won Jung, Sora Huh, Hyosun Cho, Hyojeung Kang
Journal of Microbiology.2018; 56(8): 525. CrossRef
Regulation of proliferation and invasion by the IGF signalling pathway in Epstein‐Barr virus‐positive gastric cancer
Inhye Jeong, Sun Kyoung Kang, Woo Sun Kwon, Hyun Jeong Kim, Kyoo Hyun Kim, Hyun Myong Kim, Andre Lee, Suk Kyeong Lee, Thomas Bogenrieder, Hyun Cheol Chung, Sun Young Rha
Journal of Cellular and Molecular Medicine.2018; 22(12): 5899. CrossRef
A common molecular signature of intestinal-type gastric carcinoma indicates processes related to gastric carcinogenesis
Renata Binato, Everton Cruz Santos, Mariana Boroni, Samia Demachki, Paulo Assumpção, Eliana Abdelhay
Oncotarget.2018; 9(7): 7359. CrossRef
Development of lymphoma from the donor of haploidentical stem cell transplantation: A case report
Linna Xie, Fang Zhou
Molecular and Clinical Oncology.2017; 7(5): 851. CrossRef
Implication of Leptin-Signaling Proteins and Epstein-Barr Virus in Gastric Carcinomas
Euno Choi, Sun-ju Byeon, Soo Hee Kim, Hyun Ju Lee, Hyeong Ju Kwon, HyeSeong Ahn, Dong Ha Kim, Mee Soo Chang, Joseph S Pagano
PLOS ONE.2015; 10(7): e0130839. CrossRef
Epstein Barr Virus and Helicobacter pylori Co-Infection Are Positively Associated with Severe Gastritis in Pediatric Patients
María G. Cárdenas-Mondragón, Ricardo Carreón-Talavera, Margarita Camorlinga-Ponce, Alejandro Gomez-Delgado, Javier Torres, Ezequiel M. Fuentes-Pananá, Yoshio Yamaoka
PLoS ONE.2013; 8(4): e62850. CrossRef
Cell cycle regulators, APC/β-catenin, NF-κB and Epstein-Barr virus in gastric carcinomas
Bomi Kim, Sun-Ju Byun, Young A. Kim, Ji Eun Kim, Byung Lan Lee, Woo Ho Kim, Mee Soo Chang
Pathology.2010; 42(1): 58. CrossRef
Clinical Characteristics of Monomorphic Post-transplant Lymphoproliferative Disorders
Jung-Hye Choi, Byeong-Bae Park, Cheolwon Suh, Jong-Ho Won, Won-Sik Lee, Ho-Jin Shin
Journal of Korean Medical Science.2010; 25(4): 523. CrossRef
Epstein–Barr virus antibody level and gastric cancer risk in Korea: a nested case–control study
Y Kim, A Shin, J Gwack, K-P Ko, C-S Kim, S K Park, Y-C Hong, D Kang, K-Y Yoo
British Journal of Cancer.2009; 101(3): 526. CrossRef
Nuclear Factor-Kappa B Inhibition Reduces Markedly Cell Proliferation in Epstein-Barr Virus-Infected Stomach Cancer, But Affects Variably in Epstein-Barr Virus-Negative Stomach Cancer
Jin-Yong Jeong, Jun Hee Woo, Yang Soo Kim, Sangho Choi, Sang Oh Lee, Seol-Ryoung Kil, Chul Woo Kim, Byung Lan Lee, Woo Ho Kim, Byung-Ho Nam, Mee Soo Chang
Cancer Investigation.2009; 28(2): 113. CrossRef

18,218 View
109 Download
24 Crossref

Original Articles

Results of Curative Radiation Therapy with or without Chemotherapy for Stage III Unresectable Non-Small Cell Lung Cancer: Sung-Ja Ahn, Young-Chul Kim, Kyu-Sik Kim, Kyung-Ok Park, Woong-Ki Chung, Taek-Keun Nam, Byung-Sik Nah, Ju-Young Song, Mi-Sun Yoon; Cancer Res Treat. 2005;37(5):268-272. Published online October 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.5.268

Abstract PDF PubReader ePub

Purpose

We retrospectively analyzed the patients who received curative radiotherapy for unresectable stage III NSCLC to investigate the impact of chemotherapy.

Materials and Methods

From 1998 to 2001, the records of 224 patients who completed curative radiotherapy for NSCLC were reviewed. There were 210 males and 14 females, and their median age was 64 years (range 38~83). 54 patients had stage IIIA disease and 170 patients had stage IIIB disease. Conventional radiotherapy was given and the radiation dose ranged from 50~70 Gy with a median of 60 Gy, and chemotherapy was combined for 116 patients (52%).

Results

The median survival, the 2-year, and 5-year actuarial survival rates of all 224 patients were 15 months, 30%, and 7%, respectively. The median survival of the patients with stage IIIA and IIIB disease were 21 months and 13 months, respectively (p=0.14). The median survival of patients who received chemoradiation was 18 months compared to 14 months for the patients who received RT alone (p=0.02). Among the chemoradiation group of patients, the median survival time of the patients who received 1 to 3 cycles of chemotherapy was 16 months and that for the patients who received more than 3 cycles was 22 months (p=0.07). We evaluated the effects of the timing of chemoradiation in 57 patients who received more than 3 cycles of chemotherapy. The median survival of the patients with the concurrent sequence was 25 months and that for the patients with the sequential chemotherapy was 19 months (p=0.81).

Conclusions

For advanced stage III non-small cell lung cancer patients who completed the curative radiotherapy, the addition of chemotherapy improved the survival compared to the patients who received radiotherapy alone.

Citations

Citations to this article as recorded by

Treatment for Non-Small-Cell Lung Cancer and Circulating Tumor Cells
Joel Mason, Benjamin Blyth, Michael P MacManus, Olga A Martin
Lung Cancer Management.2017; 6(4): 129. CrossRef
Clinical Responses and Prognostic Indicators of Concurrent Chemoradiation for Non-small Cell Lung Cancer
Dong-Soo Lee, Yeon-Sil Kim, Jin-Hyoung Kang, Sang-Nam Lee, Young-Kyoun Kim, Myung-Im Ahn, Dae-Hee Han, Ie-Ryung Yoo, Young-Pil Wang, Jae-Gil Park, Sei-Chul Yoon, Hong-Seok Jang, Byung-Oak Choi
Cancer Research and Treatment.2011; 43(1): 32. CrossRef

9,622 View
66 Download
2 Crossref

Treatment Outcomes of Three-Dimensional Conformal Radiotherapy for Stage III Non-Small Cell Lung Cancer: Seung-Gu Yeo, Moon-June Cho, Sun-Young Kim, Seung-Pyung Lim, Ki-Hwan Kim, Jun-Sang Kim; Cancer Res Treat. 2005;37(5):273-278. Published online October 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.5.273

Abstract PDF PubReader ePub

Purpose

To evaluate the treatment outcomes of the three-dimensional conformal radiotherapy (3D-CRT), in conjunction with induction chemotherapy, for the treatment of stage III non-small cell lung cancer (NSCLC).

Materials and Methods

Between November 1998 and March 2003, 22 patients with histologically proven, clinical stage III NSCLC, treated with induction chemotherapy, followed by 3D-CRT, were retrospectively analyzed. There were 21 males (96%) and 1 female (4%), with a median age of 68.5 (range, 42~79). The clinical cancer stages were IIIA and IIIB in 41 and 59%, respectively. The histologies were squamous cell carcinoma, adenocarcinoma and others in 73, 18 and 9%, respectively. Twenty patients (91%) received induction chemotherapy before radiation therapy. The majority of the chemotherapy regimen consisted of cisplatin and gemcitabine. Radiation was delivered with conventional anteroposterior/posteroanterior fields for 36 Gy, and then 3D-CRT was performed. The total radiation dose was 70.2 Gy. The median follow-up period was 17 months (range, 4~59 months).

Results

The median overall survival was 19 months. The two and four-year overall survival rates were 37.9 and 30.3%, respectively. The median progression-free survival was 21 months. The two and four-year progression-free survival rates were 42.1 and 21%, respectively. The prognostic factors for overall survival by a univariate analysis were age, histology and T stage (p<0.05). Acute radiation toxicities, as evaluated by the RTOG toxicity criteria, included two cases of grade 3 lung toxicity and one case of grade 2 esophagus toxicity.

Conclusion

The radiation dose could be increased without a significant increment in the acute toxicities when using 3D-CRT. It also seems to be a safe, well-tolerated and effective treatment modality for stage III NSCLC.

Citations

Citations to this article as recorded by

Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung
B. Jeremić, B. Miličić, S. Milisavljević
Clinical and Translational Oncology.2013; 15(9): 747. CrossRef

8,773 View
46 Download
1 Crossref

Oxaliplatin with Biweekly Low Dose Leucovorin and Bolus and Continuous Infusion of 5-fluorouracil (Modified FOLFOX 4) as a Salvage Therapy for Patients with Advanced Gastric Cancer: Sung-Hwan Suh, Hyuk-Chan Kwon, Ji-Hoon Jo, Young-Rak Cho, Bong-Gun Seo, Dong-Mee Lee, Sung-Hyun Kim, Jae-Seok Kim, Hyo-Jin Kim; Cancer Res Treat. 2005;37(5):279-283. Published online October 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.5.279

Abstract PDF PubReader ePub

Purpose

To determine the activity and the toxicity associated with a low dose regimen of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every two weeks (modified FOLFOX 4) as a salvage therapy for advanced gastric cancer patients.

Materials and Methods

Between December 2003 and December 2004, 33 patients were enrolled in this study. The patients were treated with oxaliplatin 85 mg/m² as a 2-hour infusion on the first day plus LV 20 mg/m² over 10 minutes. Subsequently, the patients were given a 5-FU bolus 400 mg/m² followed by a 22-hour continuous infusion of 600 mg/m² on days 1~2. The treatment was repeated at 2 week intervals.

Results

The median age of the patients was 50 years (range: 31~74), 82% (27/33) had the Eastern Cooperative Oncology Group performance status was 0 and 1. Of the 30 patients who could be evaluated for their tumor response, 8 achieved a partial response, with an overall response rate of 26.7% (95% confidence interval (CI): 20.5~32.7%). Fifteen patients (50%) showed stable disease and 7 patients (23.3%) progressed during the course of treatment. The median time from the start of chemotherapy to progression was 3.5 months (95% CI: 2.6~4.4 months) and the median overall survival time was 7.9 months (95% CI: 5.9~9.9 months). The major grade 3/4 hematological toxicity encountered included neutropenia (45.4%) and thrombocytopenia (3.0%). Neutropenic fever occurred during only 2 of the 178 cycles. The most common non-hematological toxicity encountered was grade 1/2 nausea/vomiting, which occurred in 18.2% of patients, diarrhea in 12.1% and neuropathy in 15.2%. There were no treatment related deaths.

Conclusion

The modified FOLFOX 4 regimen appears to be a safe and effective salvage therapy for advanced gastric cancer patients.

Citations

Citations to this article as recorded by

PrPC Aptamer Conjugated–Gold Nanoparticles for Targeted Delivery of Doxorubicin to Colorectal Cancer Cells
Gyeongyun Go, Chang-Seuk Lee, Yeo Min Yoon, Ji Ho Lim, Tae Hyun Kim, Sang Hun Lee
International Journal of Molecular Sciences.2021; 22(4): 1976. CrossRef
A Phase I Study of Pevonedistat Plus Capecitabine Plus Oxaliplatin in Patients With Advanced Gastric Cancer Refractory to Platinum (NCCH-1811)
Hirokazu Shoji, Daisuke Takahari, Hiroki Hara, Kengo Nagashima, Jun Adachi, Narikazu Boku
Future Science OA.2021;[Epub] CrossRef
Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan
Chihiro Kondoh, Shigenori Kadowaki, Azusa Komori, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Kei Muro
Gastric Cancer.2018; 21(6): 1050. CrossRef
Pemetrexed for previously treated patients with metastatic gastric cancer: a prospective phase II study
D S Zhang, Y Jin, H Y Luo, Z Q Wang, M Z Qiu, F H Wang, Y H Li, R H Xu
British Journal of Cancer.2015; 112(2): 266. CrossRef
Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
Ji Hyun Lee, Sung-Hyun Kim, Sung Yong Oh, Suee Lee, Hojin Lee, Hye Jung Lee, Hyo-Jin Kim
The Korean Journal of Internal Medicine.2013; 28(3): 314. CrossRef
A Retrospective Study of the Safety and Efficacy of a First-Line Treatment with Modified FOLFOX-4 in Unresectable Advanced or Recurrent Gastric Cancer Patients
Yung-Sung Yeh, Hsiang-Lin Tsai, Cheng-Jen Ma, Deng-Chyang Wu, Chien-Yu Lu, I-Chen Wu, Ming-Feng Hou, Jaw-Yuan Wang
Chemotherapy.2012; 58(5): 411. CrossRef
Modified FOLFOX-6 Therapy for Heavily Pretreated Advanced Gastric Cancer Refractory to Fluorouracil, Irinotecan, Cisplatin and Taxanes: A Retrospective Study
K. Tsuji, H. Yasui, Y. Onozawa, N. Boku, H. Doyama, A. Fukutomi, K. Yamazaki, N. Machida, A. Todaka, H. Taniguchi, T. Tsushima, T. Yokota
Japanese Journal of Clinical Oncology.2012; 42(8): 686. CrossRef
PEG‐liposomal oxaliplatin induces apoptosis in human colorectal cancer cells via Fas/FasL and caspase‐8
Chuang Yang, Hai‐Zhong Liu, Zhong‐Xue Fu
Cell Biology International.2012; 36(3): 289. CrossRef
Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group
J G Kim, S K Sohn, Y S Chae, H S Song, K-Y Kwon, Y R Do, M K Kim, K H Lee, M S Hyun, H M Ryoo, S H Bae, K U Park, W S Lee, J H Baek, H Y Chung, W Yu
British Journal of Cancer.2008; 98(3): 542. CrossRef
A Phase II Study of Paclitaxel and Cisplatin as Salvage Therapy for Patients with Advanced or Metastatic Gastric Cancer
Bong-Gun Seo, Sung Yong Oh, Dong Mee Lee, Hyun Seung Yoo, Suee Lee, Seong-Geun Kim, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim
Cancer Research and Treatment.2007; 39(1): 6. CrossRef
Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer
H.-C. Kwon, M.S. Roh, S.Y. Oh, S.-H. Kim, M.C. Kim, J.-S. Kim, H.-J. Kim
Annals of Oncology.2007; 18(3): 504. CrossRef

9,733 View
60 Download
11 Crossref

Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil and Low Dose Leucovorin in Patients with Advanced Colorectal Cancer: Yoon Mi Shin, Hae Suk Han, Seong Woo Lim, Byung Chul Kim, Kyung Suck Cheoi, Young Ook Eum, Seung Taek Kim, Ki Hyeong Lee; Cancer Res Treat. 2005;37(5):284-289. Published online October 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.5.284

Abstract PDF PubReader ePub

Purpose

The aim of this study was to evaluate the efficacy and tolerability of the oxaliplatin, 5-fluorouracil (5-FU) and low dose leucovorin (LV) combination in patients with advanced colorectal cancer.

Materials and Methods

Patients with unresectable or recurrent colorectal carcinomas were prospectively accrued. Up to one prior chemotherapy regimen was allowed. Patients received oxaliplatin, 85 mg/m², administered as a 2-hour infusion on day 1, followed by LV, 20 mg/m², as a bolus and 5-FU, 1,500 mg/m², via continuous infusion for 24 hours on days 1 and 2. Treatment was repeated every 2 weeks until disease progression or adverse effects prohibited further therapy.

Results

Between August 1999 and May 2004, 31 patients were enrolled in this study. Of the patients enrolled, 24 and 31 were evaluable for tumor response and survival analysis, respectively. The patients' characteristics included a median age of 59, with 6 (19%) having had prior chemotherapy. No patient achieved a complete response, but nine (38%) attained a partial response. Seven (29%) patients maintained a stable disease and 8 (33%) experienced increasing disease. The median duration of the response was 6 months. After a median follow-up of 9.6 months, the median time to progression was 3.8 months, with a median survival of 10.7 months. The hematological toxicities were mild to moderate, with no treatment-related mortality or infection. The major non-hematological toxicity was gastrointestinal toxicity.

Conclusion

The combination chemotherapy of oxaliplatin, low dose LV and continuous infusion of 5-FU is safe and has a cost-benefit, but is a moderately effective regimen in advanced colorectal cancer. A randomized trial comparing low and high dosages of leucovorin in the FOLFOX regimen is warranted.

Citations

Citations to this article as recorded by

Extracellular vesicles derived from Lactobacillus plantarum restore chemosensitivity through the PDK2-mediated glucose metabolic pathway in 5-FU-resistant colorectal cancer cells
JaeJin An, Eun-Mi Ha
Journal of Microbiology.2022; 60(7): 735. CrossRef
Prognostic and Predictive Role of Excision Repair Cross-complementation Group 1 and Thymidylate Synthase in Colorectal Carcinoma Patients Received FOLFOX Chemotherapy: An Immunohistochemical Study
Dalia M. Badary, Mai M. Elkabsh, Hussam H. Mady, Adel Gabr, Sana S. Kroosh
Applied Immunohistochemistry & Molecular Morphology.2020; 28(10): 741. CrossRef
Outpatient-basis Chemotherapy of Oxaliplatin, 5-fluorouracil, and Leucovorin as First-line Treatment for Patients with Metastatic or Recurrent Colorectal Cancer
Joon Ho Moon, Jong Gwang Kim, Sang Kyun Sohn, Jin Ho Baek, Yoon Young Cho, Yee Soo Chae, Byung Min Ahn, Shi Nae Kim, Soo Jung Lee, In Taek Lee, Gyu Seog Choi, Soo Han Jun
Journal of Korean Medical Science.2007; 22(3): 400. CrossRef

9,083 View
53 Download
3 Crossref

Comparison of WHO and RECIST Criteria for Response in Metastatic Colorectal Carcinoma: Jung-Hye Choi, Myung-Ju Ahn, Hyan-Chul Rhim, Jin-Woo Kim, Gang-Hong Lee, Young-Yeul Lee, In-Soon Kim; Cancer Res Treat. 2005;37(5):290-293. Published online October 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.5.290

Abstract PDF PubReader ePub

Purpose

This study compared the WHO criteria with the response evaluation criteria in solid tumors (RECIST) in the same patients with metastatic colorectal cancer in order to determine the significance of the RECIST. In addition, this study compared the estimations of medical oncologists with those of a radiologist.

Materials and Methods

Between 2002 and 2005, a total of 48 patients (male: female ratio, 29:19; median age, 58 years) with measurable lesions receiving chemotherapy for metastatic colorectal carcinoma were enrolled in this study. Two medical oncologists and one radiologist, who were blinded to the patients' condition, independently reviewed all the CT images. The results were compared using a kappa test.

Results

The kappa test for concordance between the WHO and RECIST criteria of the medical oncologists and the radiologist were 0.908 and 0.841, respectively. The level of concordance between the investigators using the WHO and RECIST were 0.722 and 0.753, respectively.

Conclusion

The RECIST criteria are comparable to the WHO criteria in evaluating the response of colorectal carcinoma, but have simple and reproducible guidelines. The use of RECIST is recommended for evaluating the treatment efficacy in clinical trials and practice.

Citations

Citations to this article as recorded by

Beyond Conventional CT: Role of Dual-Energy CT in Monitoring Response to Therapy in Abdominal Malignancies
Ali Pourvaziri, Nayla Mroueh, Rory L. Cochran, Shravya Srinivas Rao, Avinash Kambadakone
Radiology: Imaging Cancer.2025;[Epub] CrossRef
Associations between early tumor shrinkage/depth of response and survival from the ARCAD database
Hideaki Bando, Yuriko Takeda, Toshihiro Misumi, Tomomi Nishikawa, Masashi Wakabayashi, Kentaro Yamazaki, Eiji Oki, Jean-Yves Douillard, Cornelis J A Punt, Miriam Koopman, Eric Van Cutsem, Carsten Bokemeyer, Alan P Venook, Heinz-Josef Lenz, Yoshihiko Maeha
JNCI Cancer Spectrum.2025;[Epub] CrossRef
A nomogram prognostic model for early hepatocellular carcinoma with diabetes mellitus after primary liver resection based on the admission characteristics
Menghan Zhang, Qi Wang, Gongming Zhang, Guangming Li, Ronghua Jin, Huichun Xing
Frontiers in Pharmacology.2024;[Epub] CrossRef
Feasibility of an artificial intelligence system for tumor response evaluation
Nie Xiuli, Chen Hua, Gao Peng, Yu Hairong, Sun Meili, Yan Peng
BMC Medical Imaging.2024;[Epub] CrossRef
Immunotherapy Assessment: A New Paradigm for Radiologists
Vincenza Granata, Roberta Fusco, Sergio Venanzio Setola, Igino Simonetti, Carmine Picone, Ester Simeone, Lucia Festino, Vito Vanella, Maria Grazia Vitale, Agnese Montanino, Alessandro Morabito, Francesco Izzo, Paolo Antonio Ascierto, Antonella Petrillo
Diagnostics.2023; 13(2): 302. CrossRef
Study on the Application Value of Lung-RADS in the Differential Diagnosis of Benign and Malignant Lung Nodules
·马木提依力夏提
Advances in Clinical Medicine.2023; 13(12): 20190. CrossRef
Reliability and accuracy in radiographic measurements of musculoskeletal tumors
Alec S. Kellish, Sandra Miskiel, John Gaughan, Veniamin Barshay, Tae W. Kim, Christina J. Gutowski
Journal of Orthopaedic Research.2022; 40(7): 1654. CrossRef
Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
Anyue Yin, Johan G. C. van Hasselt, Henk-Jan Guchelaar, Lena E. Friberg, Dirk Jan A. R. Moes
Scientific Reports.2022;[Epub] CrossRef
Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis
Christopher M. Black, Sam Keeping, Ali Mojebi, Karthik Ramakrishnan, Diana Chirovsky, Navneet Upadhyay, Dylan Maciel, Dieter Ayers
Frontiers in Oncology.2022;[Epub] CrossRef
A quantitative and comparative evaluation of stereotactic spine radiosurgery local control: proposing a consistent measurement methodology
Ran Harel, Tehila Kaisman-Elbaz, Todd Emch, Paul Elson, Samuel T Chao, John H Suh, Lilyana Angelov
Neurosurgical Focus.2022; 53(5): E10. CrossRef
Lung-RADS Version 1.1: Challenges and a Look Ahead, From the AJR Special Series on Radiology Reporting and Data Systems
Lydia Chelala, Rydhwana Hossain, Ella A. Kazerooni, Jared D. Christensen, Debra S. Dyer, Charles S. White
American Journal of Roentgenology.2021; 216(6): 1411. CrossRef
Perillyl alcohol as a treatment for cancer: A systematic review
Aimée Obolari Durço, Lino Sérgio Rocha Conceição, Diego Santos de Souza, Carlos Anselmo Lima, Jullyana de Souza Siqueira Quintans, Márcio Roberto Viana dos Santos
Phytomedicine Plus.2021; 1(3): 100090. CrossRef
Neoadjuvant Chemotherapy for Advanced Gallbladder Cancer: Do We have Enough Evidence? A Systematic Review
Shah Naveed, Hasina Qari, Cao M Thau, Pipit Burasakarn, Abdul W Mir
Euroasian Journal of Hepato-Gastroenterology.2021; 11(2): 87. CrossRef
Objective response rate assessment in oncology: Current situation and future expectations
Nuri Faruk Aykan, Tahsin Özatlı
World Journal of Clinical Oncology.2020; 11(2): 53. CrossRef
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma
Omar Abdel-Rahman, Zeinab Elsayed
Cochrane Database of Systematic Reviews.2020;[Epub] CrossRef
What scans we will read: imaging instrumentation trends in clinical oncology
Thomas Beyer, Luc Bidaut, John Dickson, Marc Kachelriess, Fabian Kiessling, Rainer Leitgeb, Jingfei Ma, Lalith Kumar Shiyam Sundar, Benjamin Theek, Osama Mawlawi
Cancer Imaging.2020;[Epub] CrossRef
Herb–drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review
Chun Sing Lam, Lok Pui Cheng, Li Min Zhou, Yin Ting Cheung, Zhong Zuo
Chinese Medicine.2020;[Epub] CrossRef
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy
Sirisha L. Mushti, Flora Mulkey, Shenghui Tang, Harpreet Singh, Steven J. Lemery, Kirsten B. Goldberg, Rajeshwari Sridhara, Patricia Keegan, Paul G. Kluetz, Richard Pazdur, Marc R. Theoret, Julia A. Beaver
Current Oncology Reports.2020;[Epub] CrossRef
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma
Yoko Tomita, Max Moldovan, Rachael Chang Lee, Amy HC Hsieh, Amanda Townsend, Timothy Price
Cochrane Database of Systematic Reviews.2020;[Epub] CrossRef
The role of neoadjuvant chemotherapy or chemoradiotherapy for advanced gallbladder cancer – A systematic review
Abdul R Hakeem, Michail Papoulas, Krishna V Menon
European Journal of Surgical Oncology.2019; 45(2): 83. CrossRef
Polymorphisms of genes encoding drug transporters or cytochrome P450 enzymes and association with clinical response in cancer patients: a systematic review
Inthuorn Kulma, Kanyarat Boonprasert, Kesara Na-Bangchang
Cancer Chemotherapy and Pharmacology.2019; 84(5): 959. CrossRef
Identification of a 13‑gene‑based classifier as a potential biomarker to predict the effects of fluorouracil‑based chemotherapy in colorectal cancer
Zuhuan Gan, Qiyuan Zou, Yan Lin, Zihai Xu, Zhong Huang, Zhichao Chen, Yufeng Lv
Oncology Letters.2019;[Epub] CrossRef
Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond
Mizuki Nishino
American Society of Clinical Oncology Educational Book.2018; (38): 1019. CrossRef
Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe
Ralf Gutzmer, Kevin J. Harrington, Christoph Hoeller, Celeste Lebbé, Josep Malvehy, Katarina Öhrling, Gerald Downey, Reinhard Dummer
European Journal of Dermatology.2018; 28(6): 736. CrossRef
Unidimensional measurement may be superior to assess primary tumor response after neoadjuvant chemotherapy for nasopharyngeal carcinoma
Chuanben Chen, Xiurong Lin, Yuanji Xu, Penggang Bai, Youping Xiao, Yuhui Pan, Chao Li, Zhizhong Lin, Mingwei Zhang, Yunbin Chen
Oncotarget.2017; 8(29): 46937. CrossRef
Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?
Toru Mizuguchi, Toshihiko Torigoe, Fukino Satomi, Hiroaki Shima, Goro Kutomi, Shigenori Ota, Masayuki Ishii, Hiroshi Hayashi, Sumiyo Asakura, Yoshihiko Hirohashi, Makoto Meguro, Yasutoshi Kimura, Toshihiko Nishidate, Kenji Okita, Masaho Ishino, Atsushi Mi
Surgery Today.2016; 46(2): 139. CrossRef
Comparison of WHO, RECIST 1.1, EORTC, and PERCIST criteria in the evaluation of treatment response in malignant solid tumors
Mustafa Aras, Tanju Y. Erdil, Faysal Dane, Serkan Gungor, Tunc Ones, Fuat Dede, Sabahat Inanir, Halil T. Turoglu
Nuclear Medicine Communications.2016; 37(1): 9. CrossRef
Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review
Luca G. Campana, A. James P. Clover, Sara Valpione, Pietro Quaglino, Julie Gehl, Christian Kunte, Marko Snoj, Maja Cemazar, Carlo R. Rossi, Damijan Miklavcic, Gregor Sersa
Radiology and Oncology.2016; 50(1): 1. CrossRef
Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review
Jung Han Kim
Oncotarget.2016; 7(12): 13680. CrossRef
Assessment of Treatment Response Using PET
Sandip Basu, Rakesh Kumar, Rohit Ranade
PET Clinics.2015; 10(1): 9. CrossRef
Single-Lesion Measurement per Organ for Assessing Tumor Response in Advanced Gastric Cancer
Hyeong Su Kim, Ji Won Kim, Jung Han Kim, Dae Ro Choi, A. Rum Han, Min-Joeng Kim, Byung Chun Kim, Dae Young Zang
Oncology.2015; 88(2): 69. CrossRef
Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer
Hyeong Su Kim, Jung Han Kim, Ik Yang
Lung Cancer.2014; 85(3): 385. CrossRef
Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: A meta-analysis based on 44 studies
DONGNING HUANG, YANG ZHOU
Biomedical Reports.2014; 2(4): 452. CrossRef
XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis
Fanghui Ye, Zhenfang Liu, Aihua Tan, Ming Liao, Zengnan Mo, Xiaobo Yang
Cancer Chemotherapy and Pharmacology.2013; 71(3): 733. CrossRef
Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy
Matthew D. Galsky, Susan Krege, Chia‐Chi Lin, Noah Hahn, Thorsten Ecke, Erin Moshier, Guru Sonpavde, James Godbold, William K. Oh, Aristotle Bamias
Cancer.2013; 119(16): 3020. CrossRef
Diagnostic and therapeutic imaging for cancer: Therapeutic considerations and future directions
Mack Roach, Jean‐Louis Alberini, Alain Paul Pecking, Alessandro Testori, Francesco Verrecchia, Javier Soteldo, Ute Ganswindt, John L. Joyal, John W. Babich, Russell S. Witte, Evan Unger, Ronald Gottlieb
Journal of Surgical Oncology.2011; 103(6): 587. CrossRef

17,717 View
116 Download
36 Crossref

Prognostic Factors in Non-Hodgkin's Lymphoma Patients Treated by Autologous Stem Cell Transplantation: A Single Center Experience: Cheolwon Suh, Sang Hee Kim, Hyo Jung Kim, Geundoo Jang, Eun Kyung Kim, Ok Bae Ko, Shin Kim, Hee Jung Sohn, Jung Shin Lee, M. Wookun Kim, Jooryung Huh; Cancer Res Treat. 2005;37(5):294-301. Published online October 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.5.294

Abstract PDF PubReader ePub

Purpose

Autologous stem cell transplantation (ASCT) is increasingly used in patients with non-Hodgkin's lymphoma (NHL). Various clinical parameters-were evaluated to obtain significant predictors of the outcome following ASCT in patients with NHL.

Materials and Methods

Between April 1994 and December 2003, ASCT was performed on 80 patients with NHL at the Asan Medical Center.

Results

Patients had various histological subtypes and disease status. The two year progression free survival (PFS) and overall survival for all patients were 34 and 31%, respectively. A univariate analysis showed the performance status, stage, modified extranodal involvement category, International Prognostic Index (IPI) at mobilization, disease status at mobilization, and history of radiation prior to mobilization as significant predictors of the outcome following ASCT. Four risk groups, with different 2 year PFS, were identified by the age adjusted IPI at mobilization (mAAIPI): low risk 44%; low intermediate risk 40%; high intermediate risk 19%; and high risk 0% (p=.0003). A multivariate analysis revealed 3 significant factors for the PFS: disease status, prior RT and mAAIPI.

Conclusion

The mAAIPI was found to be an independent predictor of the outcome of NHL patients undergoing ASCT. This powerful prognostic tool should be used to evaluate potential candidates for ASCT.

Citations

Citations to this article as recorded by

Real-world Experience of Improvement in the Survival of Lymphoma and Myeloma Patients with Autologous Stem Cell Transplantation over a 25-year Period
Hyungwoo Cho, Shin Kim, Kyoungmin Lee, Jung Sun Park, Cheolwon Suh
The Korean Journal of Medicine.2021; 96(6): 501. CrossRef
Disease characteristics of diffuse large B‐cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience
Daria Gaut, Tahmineh Romero, David Oveisi, Grant Howell, Gary Schiller
Hematological Oncology.2020; 38(1): 38. CrossRef
Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement
Ock Bae Ko, Geundoo Jang, Shin Kim, Jooryung Huh, Cheolwon Suh
The Korean journal of internal medicine.2008; 23(4): 182. CrossRef

9,572 View
47 Download
3 Crossref

Relationship between Pre-treatment Serum SCC (squamous cell carcinoma) Antigen, Cyfra 21-1 Levels, and Survival in Squamous Cell Carcinoma of the Uterine Cervix: Ki-Hong Chang, Hee-Sug Ryu, Suk-Joon Chang, Young-Ji Byun, Jung-Pil Lee; Cancer Res Treat. 2005;37(5):302-306. Published online October 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.5.302

Abstract PDF PubReader ePub: Purpose
To determine the relationship between pretreatment serum squamous cell carcinoma (SCC) antigen and Cyfra 21-1 levels, and survival in patients with invasive squamous cell carcinoma of the cervix.
Materials and Methods
One hundred and one cervical squamous cell carcinoma patients were included. Pre-treatment levels of serum SCC antigen and Cyfra 21-1 were measured, with a 5 year minimum follow up. Thirty two recurrent disease (RD) patients were compared to 99 non-recurrent disease (NRD) patients with respect to tumor markers, FIGO stage, lesion size, lymph node status, and parametrial involvement.
Results
Pre-treatment serum SCC antigen and Cyfra 21-1 levels were significantly higher in the RD group (p<0.001). Combined serum SCC antigen and Cyfra 21-1 levels showed higher sensitivity for prediction of recurrence (90.6%). Pre-treatment SCC antigen and Cyfra 21-1 levels showed correlation with high FIGO stage, large lesion size, lymph node status, and parametrial involvement (p<0.001). Normal pre-treatment levels of SCC antigen and Cyfra 21-1 showed a 5-year survival rate of 93% and 90% respectively, while elevated levels showed significantly decreased survival rate of 63% and 59%, respectively (p<0.001). Odd ratio for cumulative survival rates were 6.87 for SCC antigen, and 5.07 for Cyfra 21-1 (p<0.001).
Conclusion
Initial pre-treatment levels of serum SCC antigen and Cyfra 21-1 are closely related to FIGO stage, lesion size, lymph node and parametrial involvement in patients with squamous cell carcinoma of the cervix. Also, these markers may be of help to predicting recurrent disease and survival rates.

9,445 View
70 Download

Tetraarsenic Oxide-mediated Apoptosis in a Cervical Cancer Cell Line, SiHa: Jeong Kim, Su-Mi Bae, Dae-Seog Lim, Sun-Young Kwak, Chang-Ki Lee, Yong-Seok Lee, IL-Ju Bae, Jin-Young Yoo, Young-Joo Lee, Chong-Kook Kim, Woong-Shick Ahn; Cancer Res Treat. 2005;37(5):307-312. Published online October 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.5.307; Retraction in: Cancer Res Treat 2007;39(1):48

14,119 View
57 Download
4 Crossref

Pattern of Apoptosis by NS398, a Selective COX-2 Inhibitor, in Hepatocellular Carcinoma Cell Lines: Mi Kyung Park, Moon Kyu Kim, Jung Chul Kim, Young Kwan Sung; Cancer Res Treat. 2005;37(5):313-317. Published online October 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.5.313

Abstract PDF PubReader ePub

Purpose

NS398, a selective COX-2 inhibitor, is known to inhibit the growth of COX-2 expressing hepatocellular carcinoma cells. The present study investigated whether the cytotoxic effect of NS398 was COX-2 dependent and whether caspases were involved in NS398-induced apoptosis in hepatocellular carcinoma cells.

Materials and Methods

The expressions of COX-2 in SNU 423 and SNU 449 hepatocellular carcinoma cell lines were examined using RT-PCR and Western blot. The cytotoxic effect of NS398 was measured using MTT in the presence or absence of caspase inhibitors. The distribution of the cell cycle and extent of apoptosis were analyzed using flow cytometry and a Cell Death Elisa kit, respectively.

Results

The expression of COX-2 was observed in SNU423 cells, but not in SNU 449 cells. NS398 treatment resulted in both dose-and time-dependent growth inhibitions, with increases in apoptotic cells in both cell lines. Treatment with the pan-caspase inhibitor, z-VAD- fmk, or the caspase-3 inhibitor, Ac-DMQD-CHO, showed no attenuation of the cytotoxic effect of NS398 in either cell line.

Conclusion

This study demonstrated that the cytotoxic effect of NS398 was independent of COX-2 expression. Caspases were also shown not to be involved in NS398-induced apoptosis in either SNU 423 or SNU 449 Korean HCC cell lines. Our data suggests the feasibility of preventing hepatocellular carcinoma with the use of COX-2 inhibitors needs to be carefully evaluated.

Citations

Citations to this article as recorded by

First study on the immunohistochemical expression of cyclooxygenase-2 and clinicopathological association in canine hepatoid gland neoplasms
Pinkarn Chantawong, Thanongsak Mamom, Sahatchai Tangtrongsup, Setthakit Chitsanoor, Hassadin Boonsriroj
Veterinary World.2022; : 2432. CrossRef
Evaluation of Cytotoxicity Effects of Chalcone Epoxide Analogues as a Selective COX-II Inhibitor in the Human Liver Carcinoma Cell Line
Bahram Daraei, Gholamreza Karimi, Pouran Makhdoumi, Afshin Zarghi
Journal of Pharmacopuncture.2017; 20(3): 207. CrossRef
RETRACTED ARTICLE: Effect of NS-398, a cyclooxygenase-2 selective inhibitor, on the cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells
Xinyan Wang, Yu Liang, Jun Wang, Min Wang
Tumor Biology.2013; 34(3): 1517. CrossRef
Gene Expression Profile of Coronary Artery Cells Treated With Nonsteroidal Anti-inflammatory Drugs Reveals Off-target Effects
Sanjeewani T. Palayoor, Molykutty J-Aryankalayil, Adeola Y. Makinde, David Cerna, Michael T. Falduto, Scott R. Magnuson, C. Norman Coleman
Journal of Cardiovascular Pharmacology.2012; 59(6): 487. CrossRef

9,268 View
39 Download
4 Crossref

First
Prev
Page of 1
Next
Last

Previous issues